Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aspirin + omeprazole is a fixed-dose combination drug containing two active ingredients: aspirin, an antiplatelet agent (salicylate), and omeprazole, a proton pump inhibitor (PPI). It is indicated for patients who require long-term low-dose aspirin therapy to reduce the risk of secondary cardiovascular or cerebrovascular events (such as heart attack or stroke) but are at increased risk of developing gastric ulcers due to chronic aspirin use. Aspirin works by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby preventing platelet aggregation and reducing thrombotic events. Omeprazole decreases gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, thus lowering the risk of gastrointestinal ulceration associated with chronic NSAID use. The combination is formulated as a coordinated delivery system—immediate-release omeprazole with enteric-coated aspirin—to optimize GI protection while maintaining antiplatelet efficacy[1][2][3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + omeprazole.